CE mark

The PAXgene Blood ccfDNA tube enables clinical laboratories to stabilize samples when they cannot be processed on the day they were collected.

The PCR-based methylation assay is intended to help predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy.

Sophia Genetics has received a CE-IVD mark for a sequencing-based test that, combined with data analytics, is meant to improve detection of leukemia.

The test has been validated for use with the same full set of female urogenital specimens that are used with Cobas NT/NG testing, as well as for use with male urine. 

The first available test on the PCR-based Accula platform will be for the diagnosis of influenza A and B virus infection.

Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.

The firm's blood-based Epi proLung lung cancer test looks for a combination of DNA methylation biomarkers.

The China Food and Drug Administration had also previously accredited both the NIFTY test and the BGISEQ sequencing platform.

The company said that it is working on cfDNA claim extensions for various PCR and NGS assays in its portfolio, which would be compatible with the new extraction system.

The robotic microbial DNA isolation and direct PCR test is designed for routine bacterial and fungal pathogen diagnosis.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.